CG Oncology, Growing Anticipation at the FDA Threshold

CG Oncology, a U.S. developer of bladder cancer therapies, reaffirmed on May 8 its plan to complete submission of the biologics license application (BLA) for its oncolytic immunotherapy candidate cretostimogene grenadenorepvec in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) by the fourth quarter of 2026, based on prior consultations with the U.S. Food and Drug Administration (FDA). The company has already filed the nonclinical and clinical modules of its first BLA and is now preparing the chemistry, manufacturing, and controls (CMC) module while responding to an FDA inspection of its manufacturing facility. Cretostimogene grenadenorepvec has received Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for monotherapy in this patient population, and CG Oncology is pursuing a rolling BLA submission. The candidate remains in clinical development and has not yet been approved by any regulatory authority.

CG Oncology (NASDAQ: CGON) is a late-stage biotech company developing cretostimogene grenadenorepvec to preserve the bladder in NMIBC patients. Its core pipeline includes BOND-003, a single-arm Phase 3 trial in high-risk BCG-unresponsive NMIBC; PIVOT-006, a randomized Phase 3 trial in intermediate-risk patients; and CORE-008, a multi-cohort Phase 2 trial evaluating both monotherapy and combination regimens in high-risk patients. The company also operates an expanded access program in the U.S. for BCG-unresponsive NMIBC patients. CG Oncology went public on the NASDAQ Global Select Market in January 2024 and is headquartered in Dallas, Texas.

In its first-quarter report released the same day, CG Oncology disclosed approximately $1.1 billion in cash, cash equivalents, and marketable securities—sufficient to fund operations through 2029. On the clinical front, the company expects to announce top-line data from PIVOT-006 and initial results from CORE-008 Cohort CX in the first half of the year, with key findings to be presented at the American Urological Association’s 2026 annual meeting in May. On April 15, CG Oncology granted stock options exercisable for 107,508 shares to President and COO Bellete Ambaw and 79,216 shares to Chief Medical Officer Vijay Kasturi, each at $67.68 per share. On April 17, director James Mulay exercised his options and sold 15,600 shares at $73.01 per share under a pre-established Rule 10b5-1 trading plan, as disclosed in a Form 4 filing. As of May 8, CG Oncology’s share price has risen roughly 210% over the past year, giving it a market capitalization near $6 billion.